Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bioequivalence of CBT124 to Avastin in Healthy Male Volunteers
NCT02747823Phase 1Unknown
- Sponsor
- Cipla BioTec
- Start
- Jun 2016
- Primary completion
- Oct 2016
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of bevacizumab biosimilar (CBT124) in cancer (3 arms), sponsored by Cipla BioTec. Primary endpoint: Area under the concentration-time curve from time 0 to infinity. Status: unknown.
02
Drugs
bevacizumab biosimilar (CBT124)
03
Conditions
cancer
Beyond the preview
Go deeper on NCT02747823.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02747823.